Vcanbio Cell & Gene Engineering Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Vcanbio Cell & Gene Engineering has been growing earnings at an average annual rate of 37.6%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 4.1% per year. Vcanbio Cell & Gene Engineering's return on equity is 2.8%, and it has net margins of 6.7%.
Belangrijke informatie
37.6%
Groei van de winst
38.3%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 11.3% |
Inkomstengroei | 4.1% |
Rendement op eigen vermogen | 2.8% |
Nettomarge | 6.7% |
Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Vcanbio Cell & Gene Engineering Corp., Ltd's (SHSE:600645) Popularity With Investors Is Under Threat From Overpricing
Sep 27Does Vcanbio Cell & Gene Engineering (SHSE:600645) Have A Healthy Balance Sheet?
Aug 26Does Vcanbio Cell & Gene Engineering (SHSE:600645) Have A Healthy Balance Sheet?
May 24Vcanbio Cell & Gene Engineering's (SHSE:600645) Soft Earnings Are Actually Better Than They Appear
May 02Subdued Growth No Barrier To Vcanbio Cell & Gene Engineering Corp., Ltd's (SHSE:600645) Price
Apr 24Opbrengsten en kosten
Hoe Vcanbio Cell & Gene Engineering geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Sep 24 | 1,593 | 107 | 732 | 201 |
30 Jun 24 | 1,594 | 109 | 731 | 200 |
31 Mar 24 | 1,610 | 109 | 742 | 193 |
31 Dec 23 | 1,590 | 106 | 744 | 183 |
30 Sep 23 | 1,581 | 131 | 724 | 154 |
30 Jun 23 | 1,584 | 131 | 739 | 154 |
31 Mar 23 | 1,538 | 115 | 734 | 150 |
31 Dec 22 | 1,555 | 113 | 738 | 146 |
30 Sep 22 | 1,552 | 79 | 794 | 141 |
30 Jun 22 | 1,536 | 109 | 793 | 128 |
31 Mar 22 | 1,563 | 146 | 793 | 133 |
31 Dec 21 | 1,535 | 155 | 787 | 134 |
30 Sep 21 | 1,509 | -69 | 753 | 121 |
30 Jun 21 | 1,467 | -97 | 715 | 127 |
31 Mar 21 | 1,409 | -87 | 687 | 114 |
31 Dec 20 | 1,319 | -127 | 647 | 112 |
30 Sep 20 | 1,351 | 89 | 618 | 125 |
30 Jun 20 | 1,338 | 68 | 624 | 113 |
31 Mar 20 | 1,342 | 25 | 633 | 112 |
31 Dec 19 | 1,387 | 50 | 635 | 108 |
30 Sep 19 | 1,355 | -182 | 676 | 115 |
30 Jun 19 | 1,345 | -189 | 692 | 109 |
31 Mar 19 | 1,320 | -43 | 693 | 103 |
31 Dec 18 | 1,321 | 59 | 707 | 101 |
30 Sep 18 | 1,333 | 317 | 676 | 84 |
30 Jun 18 | 1,327 | 322 | 652 | 91 |
31 Mar 18 | 1,434 | 116 | 703 | 124 |
31 Dec 17 | 1,321 | 10 | 673 | 102 |
30 Sep 17 | 1,238 | 60 | 629 | 80 |
30 Jun 17 | 1,113 | 22 | 579 | 52 |
31 Mar 17 | 876 | 72 | 461 | 0 |
31 Dec 16 | 838 | 38 | 423 | 0 |
30 Sep 16 | 768 | 130 | 375 | 0 |
30 Jun 16 | 740 | -64 | 362 | 0 |
31 Mar 16 | 721 | 41 | 351 | 0 |
31 Dec 15 | 709 | 208 | 353 | 0 |
30 Sep 15 | 676 | 69 | 360 | 0 |
30 Jun 15 | 615 | 305 | 340 | 0 |
31 Mar 15 | 544 | 188 | 307 | 0 |
31 Dec 14 | 477 | 35 | 287 | 0 |
30 Sep 14 | 400 | 57 | 247 | 0 |
30 Jun 14 | 389 | 29 | 238 | 0 |
31 Mar 14 | 383 | 23 | 246 | 0 |
31 Dec 13 | 361 | 7 | 242 | 0 |
Kwaliteitswinsten: 600645 has high quality earnings.
Groeiende winstmarge: 600645's current net profit margins (6.7%) are lower than last year (8.3%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 600645 has become profitable over the past 5 years, growing earnings by 37.6% per year.
Versnelling van de groei: 600645's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 600645 had negative earnings growth (-17.9%) over the past year, making it difficult to compare to the Biotechs industry average (0.08%).
Rendement op eigen vermogen
Hoge ROE: 600645's Return on Equity (2.8%) is considered low.